Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Opexa Pins Hope On Failed MS Vaccine’s Relapse Rate

This article was originally published in The Pink Sheet Daily

Executive Summary

More baseline lesions for personalized drug group cited in Phase IIb blowup

You may also be interested in...

Opexa Goes Into Hold Mode, Awaiting Secondary Progressive MS Data

Biotech cuts staff by 30%, hoping for good news from Phase IIb trial due in the fourth quarter. Status of second candidate nearing the clinic is uncertain.

Back In The Saddle: Texas Biotech Opexa Re-Enters The Clinic With MS Immunotherapy

After a series of restructurings, a manufacturing upgrade, multiple meetings with FDA and a modest fundraising, Opexa is initiating a Phase IIb trial of its renamed T-cell immune therapy Tcelna, this time in secondary progressive MS.


More unappealing Genasense news for Genta: Genta's long campaign for approval of its oncologic Genasense (oblimersen) hit another roadblock with the failure of the company's appeal of a Dec. 3, 2008 "complete response" letter. The center-level appeal failed to overturn the Office of Oncology Drug Product's conclusion that approval of the drug in chronic lymphocytic leukemia would require an additional confirmatory trial (1Pharmaceutical Approvals Monthly December 2008, In Brief). Genta has been pursuing CDER's dispute resolution process since receiving a "not approvable" letter in December 2006, contesting FDA's preference for progression-free survival over the composite endpoint used in the pivotal CLL trial. Genta made some headway in early 2008, when FDA denied the appeal but accepted complete response as an appropriate endpoint. The company proceeded to file an amended NDA with five-year follow-up data from the original Phase III trial. Genta reported that after five years, "all patients who achieved a major response (either complete or partial remission) on the Genasense treatment arm achieved superior survival compared with responders treated with chemotherapy alone." Nonetheless, "CDER concluded that new information submitted by the company in its amended [NDA] was insufficient, and the agency has recommended conducting a confirmatory clinical trial," Genta stated March 6. "While disappointed with this decision, we appreciate FDA's clarification of the path to U.S. regulatory approval." With the CLL indication stalled, Genta has been talking up use of Genasense in advanced melanoma. It expects final PFS data from the AGENDA trial in the second half of the year, with NDA submission targeted by year-end


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts